Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Relief of discomfort associated with acute painful musculoskeletal conditions,Off-label: tension headache, migraine
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Orphenadrine: hepatic N-demethylation and hydroxylation via CYP450 enzymes; Aspirin: hydrolysis to salicylate and conjugation with glycine and glucuronic acid; Caffeine: hepatic metabolism via CYP1A2.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Orphenadrine: ~30% (albumin); Aspirin: 80-90% (albumin, saturable); Caffeine: 25-36% (albumin).
30-35% bound to albumin.
Orphenadrine: ~2.5 L/kg (widespread, CNS penetration); Aspirin: 0.15-0.2 L/kg (low, primarily extracellular); Caffeine: 0.6-0.8 L/kg.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: Orphenadrine ~90%; Aspirin 40-50% (first-pass hydrolysis to salicylate); Caffeine ~100%.
Oral: 70-85% with high variability; intrathecal: 100%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), extend dosing interval to every 12-24 hours. No adjustment for mild impairment (Cr Cl 60-89 m L/min).
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% or extend interval to every 12-24 hours. Use with caution in Child-Pugh class A.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not recommended for pediatric use due to aspirin's association with Reye's syndrome and lack of safety data for orphenadrine in children.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Use lower end of dosing range (e.g., 1 tablet every 12 hours) due to increased sensitivity to anticholinergic effects and risk of aspirin-induced gastrointestinal bleeding. Avoid use in patients >80 years if possible.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
No FDA black box warning.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Avoid in patients with glaucoma, prostatic hypertrophy, or urinary retention due to anticholinergic effects; caution in elderly and those with cardiovascular disease; risk of GI bleeding with aspirin; limit caffeine intake to avoid excessive stimulation.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to any component; patients with angle-closure glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcer, prostatic hypertrophy, or bladder neck obstruction; severe renal or hepatic impairment; bleeding disorders; concurrent use of anticoagulants.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Avoid high-tyramine foods (e.g., aged cheeses, cured meats) due to orphenadrine's anticholinergic effects on gut motility. Evening meals high in caffeine may worsen insomnia. Aspirin absorption is delayed by food, but taking with food reduces GI irritation.
No specific food interactions. Avoid alcohol due to additive CNS depression.
First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may increase miscarriage risk. Second trimester: Aspirin at high doses may impair fetal renal function; orphenadrine and caffeine effects are not well-studied. Third trimester: Aspirin use after 30 weeks gestation increases risk of premature closure of ductus arteriosus and oligohydramnios; orphenadrine may cause neonatal withdrawal; caffeine may accumulate.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Aspirin and its metabolites are excreted into breast milk (M/P ratio ~0.04-0.27 for salicylate); orphenadrine is not known to be excreted; caffeine is excreted (M/P ratio ~0.5-0.76). Theoretical risk of Reye's syndrome with aspirin, and irritability in infant with caffeine. Use caution, avoid high doses.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No specific pharmacokinetic studies for the combination; however, pregnancy increases renal clearance of aspirin, requiring dose adjustments for anti-inflammatory effect. Caffeine clearance decreases in later pregnancy; orphenadrine metabolism may be altered but data insufficient. Use lowest effective dose for shortest duration.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Orphenadrine citrate has anticholinergic properties; use cautiously in patients with glaucoma, urinary retention, or myasthenia gravis. Aspirin component increases bleeding risk, especially with concurrent anticoagulants. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of salicylism with high doses or hepatic impairment.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take with food to reduce gastrointestinal upset.,Avoid alcohol while taking this medication.,Do not exceed recommended dosage; may cause dizziness or drowsiness.,Discontinue and seek medical attention if you experience signs of bleeding (e.g., black stools) or allergic reaction.,Inform your doctor if you have a history of stomach ulcers, bleeding disorders, or asthma.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
"Orphenadrine, a centrally acting muscle relaxant with sedative and anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of Ketazolam, a benzodiazepine anxiolytic. This synergistic pharmacodynamic interaction leads to enhanced sedation, impaired cognitive function, and increased risk of falls or respiratory depression, particularly in elderly or debilitated patients. The combination may also exacerbate anticholinergic side effects such as confusion and urinary retention."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, may enhance the central nervous system depressant effects of lithium cation, an antimanic agent. This additive pharmacodynamic interaction can lead to increased sedation, dizziness, and confusion, potentially impairing cognitive and motor function. Clinically, patients may experience exacerbated lithium-induced neurotoxicity, manifesting as tremor, ataxia, or altered mental status, particularly in elderly or renally impaired individuals."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of ethylmorphine, an opioid analgesic. This additive pharmacodynamic interaction may lead to enhanced sedation, respiratory depression, and psychomotor impairment, increasing the risk of falls, cognitive dysfunction, and potentially fatal respiratory compromise, particularly in elderly or debilitated patients."
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs BACLOFEN, answered by our medical review team.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is a Skeletal Muscle Relaxant that works by Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and BACLOFEN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is: 1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is classified as Category A/B. First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.